WASHINGTON — With 50 days to go before the 2020 election, President Trump is taking his wildest swing yet at the pharmaceutical industry. He’s likely to miss, but that might not matter.
There’s virtually no chance that the policies his administration rolled out on Sunday will save Americans any money on prescription medicines before Election Day. The scheme, to cap how much Medicare pays for drugs based on lower prices in foreign countries, can’t realistically be implemented by Nov. 3. Even if Trump tries a risky regulatory workaround, any changes would almost surely be delayed by a pharmaceutical industry legal challenge.